Outlook Therapeutics’ CEO presented the company’s strategy at Virtual Investor’s Why Now conference, with the webcast now available to investors. The update fol

Outlook Therapeutics’ CEO presented the company’s strategy at Virtual Investor’s Why Now conference, with the webcast now available to investors. The update follows a proposed stock-and-warrants offering, Q3 FY2026 results and FDA approval of retina drug LYTENAVA.